The MEF system: (1) permits comparison of individual KRAS mutations in the absence of other oncogenic drivers found in cancer cells; (2) is routinely and widely used to examine the selectivity of KRAS-directed therapies31–33; and (3) is used to study autophagy34. The gene discussed is KRAS; the disease is cancer.